Telix share price hits record high on strong quarter and guidance upgrade

This market darling has continued to deliver stunning top line growth.

| More on:
Happy, tablet or doctor in a laboratory with research results or positive feedback after medical data analysis. Smile, vaccine or healthcare worker reading or working on futuristic science innovation.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Telix Pharmaceuticals Ltd (ASX: TLX) share price is rising again on Thursday morning.

In early trade, the radiopharmaceuticals company's shares have hit a record high of $20.76.

Why is the Telix share price at a record high?

Investors have been bidding the company's shares higher this morning after it released an update on its performance during the second quarter.

According to the release, for the three months ended 30 June, Telix achieved total revenue of approximately US$124 million (A$189 million) This represents an increase of 55% on the prior corresponding quarter and an 8% increase on the previous quarter.

Management advised that this revenue was primarily generated from sales of Telix's prostate cancer imaging product Illuccix in the United States.

Revenue generated from sales of Illuccix in the United States was approximately US$121 million during the three months.

Guidance upgraded

In light of this strong performance, the company has upgraded its revenue guidance for FY 2024.

It now expects revenue to be in the range of US$490 million to US$510 million (A$745 million to A$776 million at current exchange rates). This represents an increase of approximately 48% to 54% on FY 2023's revenue.

Telix was previously guiding to revenue of US$445 million to US$465 million for FY 2024, which means it has lifted its guidance by a sizeable 9.9% at the mid-point. This helps explain why the Telix share price is outperforming today.

This revenue guidance is based on approved products in jurisdictions with a marketing authorisation. Telix has also reaffirmed its guidance for research and development expenditure, which remains at an expected 40% to 50% increase compared with 2023. This will be funded by earnings.

The company's managing director and CEO, Dr Christian Behrenbruch, was rightfully pleased with the quarter. He said:

We have continued to deliver excellent quarterly growth in both revenue and dose volume sales of Illuccix. We have leveraged our unrivalled scheduling flexibility and clinical differentiation, to increase our market share and minimise the impact of new entrants.

Further information, such as profitability, was not released with this update. However, investors won't have to wait long to see if Telix's strong profit growth continued during the quarter.

The company revealed that it plans to release its half year results for the six months ended 30 June on 22 August.

Following today's gain, the Telix share price is now 70% over the past 12 months.

Motley Fool contributor James Mickleboro has positions in Telix Pharmaceuticals. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Telix Pharmaceuticals. The Motley Fool Australia has recommended Telix Pharmaceuticals. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

Why is the ResMed share price taking a thumping on Thursday?

Investors seem to be signalling out ResMed for punishment.

Read more »

A woman leans forward with her hand behind her ear, as if trying to hear information.
Healthcare Shares

Why is the Cochlear share price in the red today?

Investors continue to sell the stock.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

ASX 200 healthcare stock surges amid new takeover rumours

Takeover rumours are circling again for this company.

Read more »

A elder man and woman lean over their balcony with a cuppa, indicating share rpice movement for ASX retirement shares
Healthcare Shares

'Next decade is likely to be a golden era' for ASX shares in this sector

This stock is expected to deliver healthy returns according to a fund manager.

Read more »

A group of people in a corporate setting do a collective high five.
Healthcare Shares

Guess which ASX biotech stock is surging 11% on big FDA news

Paradigm made a big step towards treating knee osteoarthritis.

Read more »

healthcare worker overseeing group of aged care residents at table
Share Gainers

This ASX All Ords share has sneakily climbed 128% over the past year

Investors have sent this under-the-radar ASX All Ords stock flying higher. But why.

Read more »

One girl leapfrogs over her friend's back.
Healthcare Shares

UBS says buy CSL shares for a double-digit return in 2025

This ASX giant could create healthy returns, according to a leading broker.

Read more »

Medical workers examine an xray or scan in a hospital laboratory.
Healthcare Shares

1 big factor to keep in mind before buying Pro Medicus shares

Investors would be wise to consider this metric.

Read more »